SignalXSignalX

VTRS Viatris

FY2024 10-K
Filed: Feb 27, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Viatris Overview

Viatris (VTRS) filed its fiscal year 2024 10-K annual report with the SEC on Feb 27, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2024 10-K

Business Overview

  • • Core business model focused on pharmaceutical manufacturing, supply chain, and commercial operations with continued divestiture activity
  • • Recent divestitures include Biocon Biologics Transaction, OTC products, women’s healthcare, and API business segments emphasized this year
+3 more insights

Management Discussion & Analysis

  • • No revenue or profitability figures reported in provided MD&A excerpt
  • • No segment performance data included in given text
+3 more insights

Risk Factors

  • • FDA warning letter and import alert on Indore, India facility, blocking 11 products from U.S., 2025 revenue impact approx. $500M, earnings impact $385M
  • • Exposure to geopolitical conflicts including Russia-Ukraine and Middle East impacting supply chains and economic conditions in Emerging Markets
+3 more insights

Financial Summary
XBRL

Revenue

$14.7B

Net Income

-$634M

Gross Margin

38.3%

Operating Margin

0.1%

Net Margin

-4.3%

ROE

-3.4%

Total Assets

$41.5B

EPS (Diluted)

$-0.53

Operating Cash Flow

$2.3B

Source: XBRL data from Viatris FY2024 10-K filing on SEC EDGAR. All figures in USD.

Other Viatris Annual Reports

FY2025 10-K

Get deeper insights on Viatris

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available